| Document Date: 2008-09-02 16:11:44
Open Document File Size: 37,45 KBShare Result on Facebook
City Philadelphia / Oklahoma City / / Company Schattauer GmbH / / Country United States / / / Event Product Issues / / Facility MD The University of Oklahoma Health Sciences Center Hematology-Oncology Section / The University of Oklahoma Health Sciences Center / / / MedicalCondition purpura / microvascular thrombosis / advanced liver cirrhosis / progressive renal failure / Initially severe ADAMTS13 deficiency / sepsis-induced disseminated intravascular coagulation / JE / disease / disseminated intravascular coagulation / Upshaw-Schulman syndrome / systemic microvascular thrombosis / endotoxemia / et al. Acquired ADAMTS13 deficiency / thrombocytopenic disorders / severe sepsis / thrombotic thrombocytopenic purpura / Congenital thrombotic thrombocytopenic purpura / thrombocytopenia / severe deficiency / critical illness / hepatic vein thrombosis / Complete deficiency / disorder / thrombotic thrombocytopenia purpura / liver cirrhosis / severe liver disease / Severe secondary deficiency / acquired thrombotic thrombocytopenic purpura / clinical syndrome / Hemolytic uremic syndrome / deficiency / Pediatr Blood Cancer / ADAMTS13 deficiency / renal failure / end-stage liver disease / Thrombosis / severe ADAMTS13 deficiency / liver disease / acute thrombotic thrombocytopenic purpura / sepsis / disorders / hemolytic-uremic syndrome / / NaturalFeature Walsh MT / / Organization University of Oklahoma / University of Oklahoma Health Sciences Center Hematology-Oncology Section / Oklahoma Health Sciences Center / / Person James N. George / N. George Colleges / / / Product activity / ADAMTS13 activity / / ProvinceOrState Oklahoma / / PublishedMedium Lippincott Williams & Wilkins / / Technology Antibodies / /
SocialTag |
© 2008 Schattauer GmbH, Stuttgart Editorial Focus Clinical insights from observations on ADAMTS13 deficiency in liver cirrhosis